ABSTRACT OBJECTIVES This study was developed to determine contemporary management of digoxin toxicity and clinical outcomes.
D
igoxin remains a therapeutic intervention in both atrial fibrillation and heart failure (HF), as described in current clinical practice guidelines (1, 2) . Although digoxin use has declined in HF and meta-analyses have raised questions about efficacy in atrial fibrillation, toxicity remains clinically relevant largely as a consequence of the drug's narrow therapeutic window (3, 4) . The risk factors for digoxin toxicity have been amply described (5) and include advanced patient age (6) , renal failure (7), metabolic disorders, and drug interactions (8) . However, little is known about hospitalizations related to toxicity including contemporary management and resource utilization. Since 1986, antidotal therapy has been available; however, its use has only been indirectly quantified (9) (10) (11) .
Therefore, the primary objectives of the study were to describe patient characteristics, hospital utilization, and outcomes of patients with digoxin toxicity, and to compare patients treated with and without digoxin immune fab (DIF).
METHODS
A retrospective cohort design was followed using the Continuous study measures were reported (mean, median, standard deviation, and range; percentiles where data appeared to be skewed). Categorical variables were reported using frequency distributions.
Given the large sample sizes, most differences between cohorts on the basic 2-way analyses were statistically significant and p values were uninformative.
Given the constraints of this nonrandomized observational study design, exploratory multivariate analyses were conducted to determine predictors of treatment with DIF, as well as the treatment effect of DIF on length of stay, while attempting to adjust for patient characteristics and selection bias.
Fixed-effects linear regression models were used to estimate DIF treatment effects for patients within a given APR-DRG, severity level, and utilization of intensive care unit, thereby controlling for unobserved variables related to their condition (13, 14) ; this was especially attractive in the current study because detailed chart data were not available for incorporation into the model. As a sensitivity analysis, a linear regression without fixed effects and with principal diagnosis, severity indices, and intensive care unit utilization as covariates was also estimated.
SAS version 9.2 (SAS Institute Inc., Cary, North
Carolina) was the statistical software utilized. Characteristics of non-DIF and DIF-treated cohorts are shown in Table 1 . Patients in both cohorts were generally older (31% $85 and 88% $65 years of age) and admitted as emergencies (78%). Race and sex were similar across cohorts. Patients in the DIF cohort were more likely than non-DIF patients to be rated as "extreme" for disease severity (37% vs. 20%), and risk of mortality (33% vs. 17%; on a scale of mild, moderate, major, extreme).
Overall, arrhythmia diagnoses accounted for 19% of principal discharge diagnoses (4.8% with atrial fibrillation or flutter). Congestive heart failure and acute renal failure each accounted for 11% of patients, and electrolyte disorders another 4%. Diastolic heart failure ICD-9-CM code 428.3x accounted for 15% of the HF diagnoses. In general, diagnoses did not differ by cohort, except for a higher portion of arrhythmia diagnoses among DIF patients than non-DIF patients (27% vs. 17%). Admission diagnoses followed a similar pattern (data not shown). Secondary diagnoses included arrhythmias in more than 90%, HF in 53%, digoxin toxicity in 90%, and chronic kidney disease in 61% of patients.
Three quarters of the admitting physicians of record in the database were internists, hospitalists, Use of Digoxin Immune Fab in Digoxin Toxicity or family practice physicians ( Table 3) .
Digoxin was administered during the hospitalization to a large portion of patients including 31% of patients receiving DIF and 14% after receipt of DIF.
OUTCOMES. The mean length of stay was longer for patients administered DIF (8.9 days) than for patients who did not receive DIF (6.6 days); in the former, the mean cost of DIF was $1,540. Overall costs ($22,328
vs. $12,032) and in-hospital mortality (14% vs. 6%)
were greater for DIF-treated patients, but 60-day readmission rates (limited to the same hospital)
were equivalent (22% and 23%, respectively) ( Table 3) and 180-day readmission rates were somewhat lower for DIF-treated patients (33% vs. 37%, p < 0.0001).
A sensitivity analysis that restricted the cohort to those patients who received DIF within 2 days did not
show a difference for in-hospital mortality or length of stay compared with the non-DIF patients. Among patients treated with DIF, those with a digoxin toxicity diagnosis had a much shorter length of stay than those who did not (7.2 days vs. 11.6 days).
Regression models adjusting for disease and severity variables, and limiting analysis to patients with a coded diagnosis of digoxin toxicity, estimated that Contemporaneous data about the incidence of toxicity cases are conflicting (3, 18, 19) . In one report, the incidence of digoxin toxicity did not decline over time, and the percentage of patients receiving DIF for digoxin toxicity appeared to have increased be- In the DIG (Digitalis Investigation Group) study, toxicity was suspected in 11.9% of cases during follow-up, but it led to hospitalization in only 2% (15) .
However, it is also noteworthy that at least in HF therapeutics, there is increasing recognition that the digoxin's clinical benefit may be limited to serum concentrations between 0.5 ng/ml and 0.9 ng/ml ( The fact that 10% of patients who received DIF did so after day 7 suggests that some toxicity cases failed usual care, were not recognized earlier in the hospital course, or developed during the hospitalization. Indeed, the mean length of stay, regardless of whether DIF was administered, was long in contrast to a prior report suggesting a mean of only
days (23).
Of some concern, digoxin is not infrequently prescribed after DIF administration. It is unlikely that its use is based on treating worsening of HF after antibody administration, although this remains a theoretical explanation. It is possible that quality initiatives will need to be designed and implemented to limit or prevent the reintroduction of digoxin during the index hospitalization with or for digoxin toxicity. Further, we noted that digoxin levels are often measured after DIF, which may not be appropriate unless the assay measures free digoxin alone.
It is uncertain whether early use of DIF leads to better outcomes. As an observational study, the ability to clarify factors explaining the difference in length of stay or cost is limited. As expected, disease severity was an important contributing factor to the length of stay and associated cost. As such, a range of multivariable analyses were conducted to attempt to correct for bias. The estimated DIF effect on length of stay was a mean reduction of 0.3 days to 0.7 days if it is assumed that only patients with a coded diagnosis of digoxin toxicity should be compared; otherwise, there was no effect.
Approximately 38% of patients receiving DIF did not have a concomitant digoxin toxicity code; these patients had more comorbidities than others receiving DIF, even after multivariable adjustment.
One possible explanation is that the sicker the patient, the greater the importance placed on coding other principal and secondary diagnoses, perhaps for reimbursement and documentation purposes.
The additional cost of DIF needs to be weighed against costs associated with nontreatment. In a sta-
that DIF is associated with cost savings over usual supportive care when the digoxin level is >3.5 ng/ml or creatinine clearance is <22 ml/min; similarly, length of stay is reduced when digoxin levels are >2.3 ng/ml for patients with non-life-threatening toxicity 
CONCLUSIONS
We have shown that digoxin toxicity was often associated with complex hospitalizations and a minority of patients (20%) was treated with DIF.
Digoxin was also prescribed in 14% of patients following administration of DIF, suggesting that opportunities exist for improved management. Use of electronic medical record data may facilitate analyses that take advantage of laboratory data and as such may allow us to further examine the management of digoxin toxicity and, in particular, the relationship between digoxin levels and specific treatments.
Further research is also needed to understand best practices, appropriate patient selection, and timing for administration of DIF, with prospective data collection to assess whether early identification and treatment can lead to shorter lengths of stay and improved outcomes.
